The optimal hemoglobin level in the cancer patient

Seminars in Oncology

Volumn 29, Issue 3, 2002, Pages 88-91

  Dicato, Mario ^a,b   Harper, Peter ^a,b  

^a Department of Neurology   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; COGNITIVE DEFECT; CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HEMOGLOBIN DETERMINATION; HUMAN; LIFE EXPECTANCY; MALIGNANT NEOPLASTIC DISEASE; ONCOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; SYMPTOMATOLOGY;

ANEMIA; HEMOGLOBINS; HUMANS; NEOPLASMS; QUALITY OF LIFE;

EID: 0036288556     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70180-2     Document Type: Article

References (25)

1. The impact of hemoglobin levels on treatment outcomes in patients with cancer
2. A new staging system for multiple myeloma based on the number of S-phase plasma cells
3. Anemia associated with non-platinum chemotherapy (CT) for Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL)
4. A phase 11 study of carboplatin and cyclophosphamide in advanced ovarian carcinoma
5. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum
6. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer
7. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients
8. Symptomatology of anemia
9. Suboptimal hemoglobin levels: Do they impact patients and their therapy?
10. Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition
11. Prevalence of anemia in cancer patients undergoing radiation therapy
12. Oxygenation status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy
13. The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience
14. The effect of hemoglobin level on radiotherapy outcomes: The Canadian experience
15. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer
16. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
17. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
18. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
19. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
20. Erythropoietin increases hemoglobin in cancer patients during radiation therapy
21. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer
22. Clinical trial experience using erythropoietin during radiation therapy
23. Marginal analysis to identify optimal hemoglobin levels to maximize quality of life improvement in anemic cancer patients receiving epoetin alfa
24. Identifying hemoglobin level for optimal quality of life: Results of an incremental analysis
25. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx